endocrine-disorders-1234399857677955-1

116
MAJOR DISORDERS MAJOR DISORDERS OF THE ENDOCRINE OF THE ENDOCRINE SYSTEM SYSTEM Nio C. Noveno, RN, MAN Nio C. Noveno, RN, MAN

Transcript of endocrine-disorders-1234399857677955-1

Page 1: endocrine-disorders-1234399857677955-1

MAJOR DISORDERS MAJOR DISORDERS OF THE ENDOCRINE OF THE ENDOCRINE

SYSTEMSYSTEMNio C. Noveno, RN, MANNio C. Noveno, RN, MAN

Page 2: endocrine-disorders-1234399857677955-1
Page 3: endocrine-disorders-1234399857677955-1

HORMONE REGULATION:HORMONE REGULATION:NEGATIVE FEEDBACK NEGATIVE FEEDBACK MECHANISMMECHANISM

If the client is healthy,the concentration of hormones

is maintained at a constant level.

When the hormone concentration rises,further production of that hormone is inhibited.

When the hormone concentration falls,the rate of production of that hormone

increases.

Page 4: endocrine-disorders-1234399857677955-1

HORMONE REGULATION:HORMONE REGULATION:NEGATIVE FEEDBACK NEGATIVE FEEDBACK MECHANISMMECHANISM

Page 5: endocrine-disorders-1234399857677955-1

DISORDERS OF THE DISORDERS OF THE ENDOCRINE SYSTEMENDOCRINE SYSTEM

PrimaryPrimaryProblem in the target gland; autonomous

SecondarySecondaryProblem in the pituitary

TertiaryTertiaryProblem in the hypothalamus

Page 6: endocrine-disorders-1234399857677955-1

ANTERIOR PITUITARY ANTERIOR PITUITARY DISORDERSDISORDERS

Page 7: endocrine-disorders-1234399857677955-1
Page 8: endocrine-disorders-1234399857677955-1
Page 9: endocrine-disorders-1234399857677955-1

HYPERPITUITARISMHYPERPITUITARISMMay be due to overactivity of gland

or the result of an adenoma

Characterized by:Excessive serum concentration

of pituitary hormones (GH, ACTH, PRL)Morphologic and functional changes

in the anterior pituitary

Page 10: endocrine-disorders-1234399857677955-1

GROWTH HORMONE GROWTH HORMONE HYPERSECRETIONHYPERSECRETION

GigantismGigantismPrior to closure

of the epiphyses; proportional growth

AcromegalyAcromegalyAfter closure

of the epiphyses; disproportional

growth

Page 11: endocrine-disorders-1234399857677955-1

HYPERPITUITARISM:HYPERPITUITARISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

AArthritisCChest: barrel-shapedRRough facial featuresOOdd sensations: hands and

feetMMuscle weakness & fatigueEEnlargement of organsGGrowth of coarse hairAAmenorrhea; breast milk

productionLLoss of vision; headachesIImpotence; increased

perspiration SSnoring

Page 12: endocrine-disorders-1234399857677955-1

HYPERPITUITARISM:HYPERPITUITARISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

Page 13: endocrine-disorders-1234399857677955-1

HYPERPITUITARISM:HYPERPITUITARISM:MANAGEMENTMANAGEMENT

MedicationMedicationBromocriptine-Cabergoline

(dopamine agonists) GH hypersecretionand prolactinoma

Ocreotide (somatostatin)

GH hypersecretion

RadiationRadiationIndicated for larger

tumors

SurgerySurgeryTrans-sphenoidal hypophysectomy

Page 14: endocrine-disorders-1234399857677955-1

TRANS-SPHENOIDAL TRANS-SPHENOIDAL HYPOPHYSECTOMYHYPOPHYSECTOMY

Post-surgery nursing care

Semi- to high- Fowler’s position Protect from infection and stressful situations Hormone replacement Constant neurologic checks MIOW to check for DI WOF CSF leak Encourage deep-breathing, but not coughing Institute measures to prevent constipation

[straining increases ICP]

Page 15: endocrine-disorders-1234399857677955-1

HYPOPITUITARISMHYPOPITUITARISM

Deficiency of one or moreanterior pituitary hormones

CausesInfections / Inflammatory disorders

Autoimmune diseasesCongenital absence

TumorSurgery / Radiation therapy

Page 16: endocrine-disorders-1234399857677955-1

HYPOPITUITARISMHYPOPITUITARISMSimmonds' diseaseSimmonds' disease

[Panhypopituitarism]Complete absence

of pituitary hormones Cachexia:

most prominent feature

Follows destructionof the pituitary

by surgery, infection, injury, or a tumor

Sheehan’s Sheehan’s syndromesyndrome

[Post-partum pituitary necrosis]

A complicationof delivery

Results from severe blood loss and hypovolemia

Pituitary ischemia

Page 17: endocrine-disorders-1234399857677955-1

HYPOPITUITARISM:HYPOPITUITARISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

HypoHypo -thermia, -glycemia, -tension

LossLoss of vision, strength, libido, & secondary sexual

characteristics

Page 18: endocrine-disorders-1234399857677955-1

HYPOPITUITARISM:HYPOPITUITARISM:MANAGEMENTMANAGEMENT

MedicationMedicationHormonal substitution

[maybe for life]

CorticosteroidsLevothyroxine

Androgen / EstrogenGrowth hormone

RadiationRadiationIndicated for larger

tumors

SurgerySurgeryTrans-sphenoidal hypophysectomy

Page 19: endocrine-disorders-1234399857677955-1

POSTERIOR PITUITARY POSTERIOR PITUITARY DISORDERSDISORDERS

Page 20: endocrine-disorders-1234399857677955-1
Page 21: endocrine-disorders-1234399857677955-1
Page 22: endocrine-disorders-1234399857677955-1

DIABETES INSIPIDUSDIABETES INSIPIDUSCharacterized by massive polyuriadue to either lack of ADH or renal

insensitivity

Central DICentral DI

Due to a deficiency in ADH production

Nephrogenic DINephrogenic DI

Due to a defect in the kidney tubulesthat interferes with water absorption

Polyuria is unresponsive to ADH,which is secreted normally.

Page 23: endocrine-disorders-1234399857677955-1

DIABETES INSIPIDUS:DIABETES INSIPIDUS:DIAGNOSTICSDIAGNOSTICS

Fluid deprivation testAdministration of desmopressin24-hour urine collection

for volume, glucose, and creatinine

Serum for glucose, urea nitrogen, calcium, uric acid, potassium, sodium

Page 24: endocrine-disorders-1234399857677955-1

DIABETES INSIPIDUS:DIABETES INSIPIDUS:MANAGEMENTMANAGEMENT

Central DI:Desmopressin, Lypressin [intranasal]Vasopressin tannate in oil [IM]

Nephrogenic DI:Indomethacin-

-hydrochlorothiazide-desmopressin-amiloride

Clofibrate, chlorpropamide

Page 25: endocrine-disorders-1234399857677955-1

SYNDROME OF INAPPROPRIATE SYNDROME OF INAPPROPRIATE ADHADH

Disorder due to excessive ADH release

Clinical Manifestations

Persistent excretion of concentrated urineSigns of fluid overload

HyponatremiaLOC changes

No edema

Page 26: endocrine-disorders-1234399857677955-1

SIADH: DIAGNOSTICSSIADH: DIAGNOSTICS

Low serum sodium [<135 mEq/L] Low serum osmolality High urine osmolality [>100

mOsmol/kg] High urine sodium excretion [>20

mmol/L] Normal renal function: low BUN

[<10 mg/dL]

Page 27: endocrine-disorders-1234399857677955-1

SIADH: MANAGEMENTSIADH: MANAGEMENTMaintain fluid

balance MIOW Fluid restriction Loop diuretic

[If with evidence of fluid overload]

Lithium or demeclocycline[Chronic treatment]

Maintain Na balance Increased Na

intake Emergency

treatment of 3% NaCl, followed by furosemide[If serum Na <120, or if patient is seizing]

Excessively rapid correction of hyponatremia may cause central pontine myelinolysis!

Page 28: endocrine-disorders-1234399857677955-1

THYROID DISORDERSTHYROID DISORDERS

Page 29: endocrine-disorders-1234399857677955-1
Page 30: endocrine-disorders-1234399857677955-1
Page 31: endocrine-disorders-1234399857677955-1

THYROID FUNCTION TESTSTHYROID FUNCTION TESTS

Fine-needle aspiration biopsyFine-needle aspiration biopsy

Sampling of thyroid tissue to detect malignancy

Initial test for evaluation of thyroid massesResults

Negative [benign]Positive [malignant]

Indeterminate [suspicious]Inadequate [non-diagnostic]

Page 32: endocrine-disorders-1234399857677955-1

THYROID FUNCTION TESTSTHYROID FUNCTION TESTS

Nursing Implications

Determine whether the patient has taken medications or agents that contain iodine [antiseptics, multivitamins, cough syrup, amiodarone] because these may alter the test results.

Assess for allergy to iodine or shellfish.

For scans, tell patient that radiation is only minimal.

Page 33: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISMHYPERTHYROIDISM

Increased basal metabolic rate (BMR)Increased basal metabolic rate (BMR)

CausesGrave’s disease (autoimmune)

Initial manifestation of thyroiditisTSH-screening pituitary tumor

Toxic adenomaFactitious thyrotoxicosis

Amiodarone therapy

Page 34: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISM:HYPERTHYROIDISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

GGI hypermotility

RRapid weight lossAApprehension

VVolume deficit; voracious appetiteEExophthalmos; erratic menses

SSystolic BP elevated; sweating

[tremors, tachycardia, palpitations]

in secondary disease

in primary diseaseTSTSHH

Page 35: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISM:HYPERTHYROIDISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

Page 36: endocrine-disorders-1234399857677955-1

THYROID STORM / THYROTOXIC THYROID STORM / THYROTOXIC CRISISCRISIS

Marked deliriumSevere tachycardia

VomitingDiarrhea

DehydrationHigh fever

Occurs in patientswith existing

but unrecognized thyrotoxicosis,

stressful illness,thyroid surgery, RAI

Increased systemic adrenergic activity:

Severehypermetabolism

Page 37: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISM:HYPERTHYROIDISM:MANAGEMENTMANAGEMENT

Anti-thyroid drugsAnti-thyroid drugsPropylthiouracil (PTU); methimazolePropylthiouracil (PTU); methimazole

Blocks thyroid hormone (TH) synthesis

Used for pregnant women and patientswho have refused surgery or RAI treatment

During pregnancy, PTU is DOC.1% of infants born to mothers on anti-thyroid therapy will be hypothyroid.

WOF agranulocytosis.

Page 38: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISM:HYPERTHYROIDISM:MANAGEMENTMANAGEMENT

RAI (¹³¹I), K or Na iodide, SSKI (Lugol’s)RAI (¹³¹I), K or Na iodide, SSKI (Lugol’s)Adjunct to other anti-thyroid drugsin preparation for thyroidectomy

Treatment for thyrotoxic crisis

Inhibit release and synthesis of THDecrease vascularity of the thyroid gland

Decrease thyroidal uptake of RAI

Page 39: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISM:HYPERTHYROIDISM:MANAGEMENTMANAGEMENT

Medications to relieve the symptomsrelated to the increased metabolic rate:

Digitalis, propranolol (Inderal), phenobarbitalDigitalis, propranolol (Inderal), phenobarbital

Well-balanced, high-calorie dietwith vitamin and mineral supplements

Subtotal or total thyroidectomy

Page 40: endocrine-disorders-1234399857677955-1

RAI THERAPYRAI THERAPY::

NURSING IMPLICATIONSNURSING IMPLICATIONS NPO post-midnight prior to administration

[Food may delay absorption]

After initial dose:Urine and saliva slightly radioactive x

24HVomitus highly radioactive x 6-8HInstitute full radiation precautions.

Instruct the patient to use appropriate disposal methods when coughing and expectorating.

Page 41: endocrine-disorders-1234399857677955-1

K OR NA IODIDE, SSKI (LUGOL’S)K OR NA IODIDE, SSKI (LUGOL’S)::

NURSING IMPLICATIONSNURSING IMPLICATIONS Dilute oral doses in water or fruit juice

and give with meals to prevent gastric irritation, to hydrate the patient, and to mask the very salty taste.

Give iodides through a straw to avoid teeth discoloration.

Force fluids to prevent fluid volume deficit.

Warn patient that sudden withdrawal may precipitate a thyrotoxic crisis.

Store in a light-resistant container.

Page 42: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISMHYPOTHYROIDISMA state of low serum TH levels

or cellular resistance to TH

AAutoimmuneDDevelopment

alDDietary

IIodine deficiencyOOncologic

DDrugsIIatrogenicNNon-

thyroidalEEndocrine

Page 43: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISMHYPOTHYROIDISM

CausesChronic autoimmune [Hashimoto’s]

thyroiditisHypothalamic failure to produce TRH

Pituitary failure to produce TSHInborn errors of TH synthesis

Thyroidectomy / Radiation therapyAnti-thyroid therapy

Iodine deficiency

Page 44: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISMHYPOTHYROIDISMClassified according to the time of life in which it

occurs

CretinismCretinismIn infants and young children

Lymphocytic thyroiditisLymphocytic thyroiditisAppears after 6 years of age

and peaks during adolescence; self-limiting

Hypothyroidism without myxedemaHypothyroidism without myxedemaMild thyroid failure in older children and adults

Hypothyroidism with myxedemaHypothyroidism with myxedemaSevere thyroid failure in older individuals

Page 45: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISM:HYPOTHYROIDISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

DDry, brittle hair; dry, coarse skin

EEdema (periorbital)RReduced BMR [bradycardia,

bradypnea]AApathy; anorexia; anemiaIIncreased weight; intolerance to

coldLLethargy; loss of libido

in secondary disease

in primary diseaseTSTSHH

EEnlarged tongueDDrooling

Page 46: endocrine-disorders-1234399857677955-1

MYXEDEMA COMAMYXEDEMA COMA

Hypotension

Bradycardia

Hypothermia

Hyponatremia

Hypoglycemia

Respiratory failure

Coma

Precipitating Factors

Acute illness

Rapid withdrawalof thyroid medication

Anesthesia / Surgery

Hypothermia

Opioid use

Page 47: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISM:HYPOTHYROIDISM:MANAGEMENTMANAGEMENT

PreventionProphylactic iodine supplements to decrease

the incidence of iodine-deficient goiter

Symptomatic casesHormonal replacement

Levothyroxine (Synthroid)Levothyroxine (Synthroid)Liothyronine (Cytomel)Liothyronine (Cytomel)

Liotrix (Thyrolar)Liotrix (Thyrolar)Dosage increased q 2-3 weeksespecially in elderly patients

Page 48: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISM:HYPOTHYROIDISM:MANAGEMENTMANAGEMENT

Tell patient to WOF:Chest pain, palpitations, sweating,

nervousness, and other S/S of overdosage

Instruct the patient to take TH at the same time each day to maintain constant hormone levels.Suggest a morning dosage to prevent insomnia.

Monitor apical pulse and BP.If pulse >100 bpm, withhold drug.

Page 49: endocrine-disorders-1234399857677955-1

HYPOTHYROIDISM:HYPOTHYROIDISM:NURSING INTERVENTIONSNURSING INTERVENTIONS

Diet: high-bulk, low-calorie

Encourage activityMaintain warm

environmentAdminister catharticsand stool softeners

To preventmyxedema coma,

tell patient to continue course of thyroid

medication even if symptoms subside.

Maintain patent airwayAdminister medications:

Synthroid, glucose, corticosteroids

IV fluid replacementWrap patient in blanket

Treat infectionor any underlying illness

Page 50: endocrine-disorders-1234399857677955-1

PARATHYROID PARATHYROID DISORDERSDISORDERS

Page 51: endocrine-disorders-1234399857677955-1
Page 52: endocrine-disorders-1234399857677955-1
Page 53: endocrine-disorders-1234399857677955-1

HYPERPARATHYROIDISMHYPERPARATHYROIDISM

PrimaryPrimary

Single adenomaGenetic disorders

Multiple endocrine neoplasias

SecondarySecondary

RicketsVitamin D deficiencyChronic renal failure

Phenytoin or laxative abuse

Page 54: endocrine-disorders-1234399857677955-1

HYPERPARATHYROIDISM:HYPERPARATHYROIDISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

CConstipation

AApathyLLordosisCCardiac

dysrhythmiasUUpset GITLLow energylevelsIIncreased BP

PO4PTHCalcium

Alkaline phospatase

Page 55: endocrine-disorders-1234399857677955-1

HYPERPARATHYROIDISM:HYPERPARATHYROIDISM:MANAGEMENTMANAGEMENT

Surgery to remove adenoma

Force fluids; limit dietary calcium intake

For life-threatening hypercalcemia:Furosemide

Bisphosphonates[Etidroanate (Didrodinel), pamidronate]

Calcitonin (Cibacalcin, Miacalcin)

Plicamycin (Mithracin) + glucocorticoidMithramycin

Page 56: endocrine-disorders-1234399857677955-1

HYPOPARATHYROIDISMHYPOPARATHYROIDISM

Causes

Congenital absenceor malfunction of the parathyroids

Autoimmune destruction

Removal or injury to one or moreparathyroids during neck surgery

Massive thyroid radiation therapy

Ischemic parathyroid infarction during surgery

Page 57: endocrine-disorders-1234399857677955-1

HYPOPARATHYROIDISM:HYPOPARATHYROIDISM:CLINICAL MANIFESTATIONSCLINICAL MANIFESTATIONS

DDyspnea; dysrhythmias

EExtremities: tinglingFFotophobia

IIncreased bone densityCChvostek sign; crampsIIrritability

TTrousseau sign; tetany

PO4PTHCalcium

Alkaline phospatase

Page 58: endocrine-disorders-1234399857677955-1

HYPERTHYROIDISM:HYPERTHYROIDISM:MANAGEMENTMANAGEMENT

IV Ca chloride or gluconate [emergency treatment]

DOC post-thyroidectomy

Oral Ca salts (Ca carbonate or gluconate)

Vitamin D supplementationIncrease intestinal Ca absorption

Dihydrotachysterol, ergocalciferol

Page 59: endocrine-disorders-1234399857677955-1

Trousseau’s & Chvostek’sElevated serum PO4; low Ca2+TinglingAlkalosis; ArrhythmiasNarrowing of airwayIrritabilityCramps

Page 60: endocrine-disorders-1234399857677955-1

HYPOPARATHYROIDISM

Parathormone injections [in acute attacks]

WOF allergiesDiet: High-calcium [spinach], low-

phosphate [milk, cheese, egg yolks]

Al(OH)2, Gelusil, Amphogel p.c. Pentobarbital (Nembutal)

[calm environment]

Page 61: endocrine-disorders-1234399857677955-1

PHEOCHROMOCYTOMA

Page 62: endocrine-disorders-1234399857677955-1

ADRENAL GLANDS

Page 63: endocrine-disorders-1234399857677955-1

ADRENAL MEDULLA

Release cathecholamines Epinephrine Norephinephrine

Released during “fight or flight” situations (sympathetic effect)

Page 64: endocrine-disorders-1234399857677955-1

PHEOCHROMOCYTOMA

Adrenal tumorAdrenal tumor

Increased Epi and NEpiIncreased Epi and NEpi

HeredityHeredity

Page 65: endocrine-disorders-1234399857677955-1

PHEOCHROMOCYTOMA

HHeadache

AAnxiety

NNausea

EEye disturbances

SSevere hypertension

Page 66: endocrine-disorders-1234399857677955-1

PHEOCHROMOCYTOMA

BPBP

HRHR

DiaphoresisDiaphoresis

BMRBMR

VMAVMA

GlucoseGlucose

Page 67: endocrine-disorders-1234399857677955-1

PHEOCHROMOCYTOMAAdrenalectomy

Steroid treatment

Antihypertensive and antidysrhythmic

nitroprusside (Nipride) propranolol (Inderal)

phentolamine (Regitine)

Page 68: endocrine-disorders-1234399857677955-1

PHEOCHROMOCYTOMA

MBP / MIOFluid replacements

Decrease environmental stimulation

Maintenance doses of steroids Follow-up check up

24-hour urine specimens [VMA and catecholamine studies]Avoid: coffee, chocolate, beer, wine,

citrus fruit, bananas, and vanilla 24h before test

Page 69: endocrine-disorders-1234399857677955-1

ADDISON'S DISEASE

Page 70: endocrine-disorders-1234399857677955-1

ADRENAL CORTEX HORMONES

GlucocorticoidsCortisol, corticosteroneIncrease blood glucose levels by

increasing rate of gluconeogenesisIncrease protein catabolismIncrease mobilization of fatty acidsPromote sodium and water retentionAnti-inflammatory effectAid the body in coping with stress

Page 71: endocrine-disorders-1234399857677955-1

ADRENAL CORTEX HORMONES

MineralocorticoidsAldosterone, Corticosterone,

DeoxycorticosteroneRegulate fluid and electrolyte balanceStimulate reabsorption of sodium,

chloride and waterStimulate potassium excretion

Under the control of Renin-Angiotensin-Aldosterone system (RAAS)

Page 72: endocrine-disorders-1234399857677955-1
Page 73: endocrine-disorders-1234399857677955-1

ADRENAL CORTEX HORMONES

Sex hormonesAndrogens, EstrogensInfluences the development of sexual characteristics

Page 74: endocrine-disorders-1234399857677955-1
Page 75: endocrine-disorders-1234399857677955-1

ADDISON'S DISEASE

Hyposecretion of adrenocortical hormones

Destruction of the cortex

Idiopathic atrophy

Page 76: endocrine-disorders-1234399857677955-1

ADDISON'S DISEASE

WWeakness

EExcess stress

AA / N / V / D

KK & ACTH elevation; Low Na, BP, cortisol, glucose

Page 77: endocrine-disorders-1234399857677955-1
Page 78: endocrine-disorders-1234399857677955-1

ADDISON'S DISEASE

Replacement of hormones Hydrocortisone;

FludrocortisonePNSS (0.9 NaCl)

Dextrose Diet:

High-CHO & CHONLow potassium, high sodium

Page 79: endocrine-disorders-1234399857677955-1

ADDISON'S DISEASE

VS, weight, and serum glucose level

24-hour urine specimens[LOW 17- hydroxycorticosteroids

& 17-ketosteroids]Electrolyte levels: K; Na

Bronze-skinChanges in energy or activity

Page 80: endocrine-disorders-1234399857677955-1

ADDISON’S DISEASE

Page 81: endocrine-disorders-1234399857677955-1

ADDISON'S DISEASE

MVS [4x / day]Infection, Addisonian crisis,

dehydrationMIOW / MBP / MBG

Give steroids with milk or an antacid

Avoid: Contacts & Stress

Page 82: endocrine-disorders-1234399857677955-1

CUSHING'S SYNDROME

Page 83: endocrine-disorders-1234399857677955-1

CUSHING'S DISEASE

AAdrenal drenal hyperplasia / tumorhyperplasia / tumor

CCushing’s diseaseushing’s diseaseTTumor-secreting umor-secreting

ACTHACTHHHypothalamicypothalamic

Page 84: endocrine-disorders-1234399857677955-1

BBuffalo humpUUnusual behavior (depression,

personality changes, fatigability)

FFacial features (moonface, hirsutism in women)

FFat (truncal obesity)AACTH and cortisol in blood elevated;

LLoss of muscle massOOverextended skin (abdominal striae with easy bruisability)

Page 85: endocrine-disorders-1234399857677955-1

HHypertension, hyperglycemia, hypernatremia

UUrinary cortisol elevated

MMenstrual irregularities

PPorosity of bones (osteoporosis)

Page 86: endocrine-disorders-1234399857677955-1

CUSHING’S SYNDROME

Page 87: endocrine-disorders-1234399857677955-1

CUSHING'S SYNDROME

Remove exogenous steroids

Hypophysectomy or irradiation

Adrenalectomy

Page 88: endocrine-disorders-1234399857677955-1

CUSHING'S SYNDROME

Cyproheptadine (Periactin)Metyrapone

Mitotane (Lysodren)Aminoglutethamide

(Cytadren)Potassium supplements

High-CHON; Low Na

Page 89: endocrine-disorders-1234399857677955-1

CUSHING'S SYNDROME

MVS, MIOW, MBP, MBGElectrolyte levels: Na & K

Urine specimens[LOW 17- hydroxycorticosteroids & 17-

ketosteroids]Physical appearance

Changes in coping & sexuality[verbalization]

Stress reduction

Page 90: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Page 91: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Insulin resistance [GDM, age]

Failure in productionBlockage of insulin supply

Autoimmune responseExcess body fat

Heredity

Page 92: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Type I [juvenile ]/IDDM

Type II [adult- onset type]/ NIDDM

gradual onset diet and exercise obesity

Pancreatectomy, Cushing's syndrome, drugs

Page 93: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Low insulin leads toLow insulin leads to:

Hyperglycemia Glucosuria

Polyuria Gluconeogenesis

Page 94: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

ComplicationsMicrovascular

Retinopathy & Renal failureMacrovascular

CV and PVDPeripheral neuropathy

Page 95: endocrine-disorders-1234399857677955-1

P P olyuriolyuriaaolydipsiolydipsiaaolypholyph

agiaagiaruritururitussaresthesaresthes

iaiaoor oor healinghealingoor oor

eyesighteyesight

Page 96: endocrine-disorders-1234399857677955-1

NormalNormal ImpairedImpaired DMDM

FBSFBS <110mg/dl 110-125mg/dl ≥126mg/dl

2H 2H OGTOGT

TT<140mg/dl

≥140; <200mg/dl

≥ 200 mg/dl

Page 97: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

DietDietcomplex CHO [50% to 60%]

water-soluble fiberoat, bran, peas, beans, pectin-

rich FVCHON [12% to 20%]

60 and 85 gCHOO [<30%]

70 to 90 g/day / MUFA

Page 98: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Insulin dose adjustments Insulin dose adjustments

depend ondepend on:physical and emotional

stressesspecific type of insulin

condition and needs of the client

Page 99: endocrine-disorders-1234399857677955-1

InsulinInsulin OnsetOnset PeakPeak DurationDuration

Ultra rapid acting insulin analog

(humalog)10-15 min 1 H 3 H

SAI (humulin regular) ½ - 1 H 2-4 H 4-6 (8) H

IAI (humulin lente, Humulin NPH) 3-4 H 4-12 H 16-20 H

LAI (Protamine zinc, humulin ultralente) 6-8 H 12-16 H 20-30 H

Premixed insulin(NPH-regular

[80-20, 70-30, 50-50])

½-1 H 2-12 H 18-24 hrs

Insulin glargine (Lantus )

Slower than NPH

No Peak 24 H

Page 100: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Somogyi effectSomogyi effectEpinephrine & Glucagon

Glycogenolysis [iatrogenically-induced

hyperglycemia]

Lowering insulin dosage at night

MBG

Page 101: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Insulin pumpInsulin pump1) Basal doses of regular insulin

delivered every few minutes bolus doses delivered pc

2) Appropriate amount of insulin for 24 hours plus priming is drawn into syringe

3) The administration set is primed and needle inserted aseptically, usually into abdomen

Page 102: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Client teaching points:1. Proper insulin preparation

using aseptic technique2. When to remove the pump

(e.g., before showering or sexual relations)

3. MBG at home

Page 103: endocrine-disorders-1234399857677955-1

INSULIN ADMINISTRATIONIncreases the hypoglycemic effects of

insulinAspirin, alcohol, oral anticoagulants, oral

hypoglycemics, beta blockers, tricyclic antidepressants, tetracycline, MAOIs

Increases blood glucose levelsGlucocorticoids, thiazide diuretics, thyroid agents, oral contraceptives

Increase the need for increased insulin dose

Illness, infection, and stress

Page 104: endocrine-disorders-1234399857677955-1

ORAL HYPOGLYCEMIC AGENTS

SulfonylureasSulfonylureasPromotes increase insulin secretion from

pancreatic beta cells through direct stimulation

First Generation Agents:Acetohexamide

Tolbutamide (Orinase)Tolzamide (Tolinase)

Chlorpropamide (Diabenese)Second Generation Agents:Glipizide (Minidiab, Glucotrol)

Glyburide (DiaBeta, Glynase, Micronase)Glimepiride (Amaryl)

Page 105: endocrine-disorders-1234399857677955-1

ORAL HYPOGLYCEMICS

BiguanidesBiguanidesReduces hepatic production of

glucose by inhibiting glycogenolysis

Decrease the intestinal absorption of glucose and improving lipid profile

Agents:Phenformin

Metformin (Glucophage, Glucophage XR)

Buformin

Page 106: endocrine-disorders-1234399857677955-1

ORAL HYPOGLYCEMICS

Alpha-glucosidase Alpha-glucosidase inhibitorsinhibitors

Inhibits alpha-glucosidase enzymes in the small intestine and alpha

amylase in the pancreasDecreases rate of complex

carbohydrate metabolism resulting to a reduced rate postprandially

Agents:Acarbose (Precose, Gluconase, Glucobay)

Miglitol (Glyset)

Page 107: endocrine-disorders-1234399857677955-1

ORAL HYPOGLYCEMICS

ThiazolidinedionesThiazolidinedionesEnhances insulin action at the cell and

post-receptor site and decreasing insulin resistance

Agents:

Pioglitazone (Actos)Rosiglitazone (Avandia)

Rosiglitazone + Metformin (Avandamet)

Page 108: endocrine-disorders-1234399857677955-1

GLYCOSYLATED HEMOGLOBIN (HBA1C)

Reflects Reflects effectiveness of effectiveness of

treatmenttreatment

< 7.5% (good control)7.6% - 8.9% (fair control)

> 9% (poor control)

Page 109: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

Administer insulinAdminister insulinsterile technique

rotating injection sitesdosage / types / strengths /

peak CHO source

AvoidAvoid: tight shoes; smoking; heat

Page 110: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

hypoglycemiahypoglycemiaHeadache

NervousnessDiaphoresis

Rapid, thready pulseSlurred speech

Page 111: endocrine-disorders-1234399857677955-1

THE CLIENT IS TIRED!

TIrritability

Restlessness

EDiaphoresis

Hypoglycemia: <50 Hypoglycemia: <50 mg/dLmg/dL

Causes: Overtreated hyperglycemia Increased exercise β-blockers Gastric paresis Alcohol intake Erratic insulin absorption

achycardia

xcessive hungerxcitability

remors

Page 112: endocrine-disorders-1234399857677955-1

Mild:ShakinessTremorsExcessive

hungerParesthesiasPallorDiaphoresis

Rx:

10-15 gm carbohydrate 2 oz. (1 small tube of)

cake icing4 oz. orange juice6 oz. regular soda6-8 oz 2% skim milk(4 to) 10 pieces of hard

candy

Page 113: endocrine-disorders-1234399857677955-1

Moderate:Drowsiness Impaired judgmentDouble or blurred vision

Headache Inability to concentrate

Mood swings Irritability Slurred speech

Rx:

20-30 gm carbohydrate

Glucagon 1 mg SQ/IM

Page 114: endocrine-disorders-1234399857677955-1

Severe:

Seizures

Unconsciousness

Disorientation

Rx:

25 gm D50 dextrose IV

Glucagon 1 mg IM/IV

Page 115: endocrine-disorders-1234399857677955-1

DIABETES MELLITUS

diabetic comadiabetic comaRestlessness

Hot, dry, flushed skinThirst

Rapid pulseNausea

Fruity odor to breath

Page 116: endocrine-disorders-1234399857677955-1

MAJOR DISORDERS MAJOR DISORDERS OF THE ENDOCRINE OF THE ENDOCRINE SYSTEMSYSTEMTHANK YOU!

Nio C. Noveno, RN, MANNio C. Noveno, RN, MAN